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processes. In general, permeation occurs via passive or 
carrier-mediated transport mechanisms. Passive transport 
can result from the passage of molecules through the cell 
membrane itself (via diffusion through the membrane or 
pores that exist on the membrane, ie, transcellular perme-
ation) or by passage between adjacent cells (through tight 
junctions, ie, paracellular permeation). In contrast, active 
transport processes usually involve specific transporter 
proteins responsible for the absorption of amino acids, 
oligopeptides, organic anions, organic cations, carbohy-
drates, and other molecules.1 
Considerable evidence indicates that the integrity 
of the intestinal barrier is diminished as a result of 
burn injury and other conditions associated with profound 
inflammation.2-7 In burn injury, gut mucosal weight, 
protein, and DNA content are all decreased, leading to 
a decrease in functional surface area of the small 
bowel.8-11 Although the precise cause of altered gut 
integrity is unknown, studies suggest that inflamma-
tory cytokines (both local and systemic) and intestinal 
The intestinal epithelium is an efficient, selective barrier that facilitates the absorption of nutrients while simultaneously limiting the absorption of 
antigenic and noxious material. The permeation of mac-
romolecules through the intestine is mediated via several 
Intestinal Dipeptide Absorption Is  
Preserved During Thermal Injury and  
Cytokine Treatment
David R. Foster, PharmD1; Jeffrey P. Gonzales, PharmD2;  
Gordon L. Amidon, PhD3; and Lynda S. Welage, PharmD, FCCP4
Financial disclosure: this work was supported in part by the American College of Clinical Pharmacy Research Institute-Bayer 
Pharmaceuticals Critical Care Fellowship and NIH/NIGMS 5 R01 GM37188.
From the 1Department of Pharmacy Practice, Purdue University 
School of Pharmacy and Pharmaceutical Sciences, Indianapolis, 
Indiana; 2Department of Pharmacy Practice and Science, 
University of Maryland School of Pharmacy, Baltimore, Maryland; 
3Department of Pharmaceutical Sciences, University of Michigan, 
College of Pharmacy, Ann Arbor, Michigan; 4Department of 
Clinical, Social and Administrative Sciences, University of 
Michigan College of Pharmacy, and Department of Pharmacy 
Services, University of Michigan Hospitals, Ann Arbor, 
Michigan.
Received for publication May 23, 2008; accepted for publication 
July 24, 2008.
Address correspondence to: Lynda S. Welage, PharmD, University 
of Michigan College of Pharmacy, 428 Church Street, Ann 
Arbor, MI 48109-1065; e-mail: lswelage@umich.edu.
Original Communication
Background: Intestinal barrier function is impaired during ther-
mal injury; however, the effects of thermal injury on the absorp-
tion of dietary peptides are not well characterized. The purpose 
of this study was to determine the impact of thermal injury on 
dipeptide absorption in rats and to describe the influence of 
inflammatory cytokines on the expression of the oligopeptide 
transporter PEPT1 and dipeptide permeability in cultured intes-
tinal cells (Caco-2 cells). Methods: Sprague Dawley rats were 
assigned to 30% body surface area burn (n = 7) or sham (n = 8) 
groups. Twenty-four hours following burn/sham, the proximal 
jejunum was cannulated. The jejunal segment was perfused with 
buffer containing the dipeptide glycylsarcosine (Gly-Sar), and 
intestinal permeability (Peff) was calculated. For in vitro experi-
ments, Caco-2 cells were grown on permeable supports and 
treated with tumor necrosis factor (TNF)-α, interleukin (IL)-6, 
and IL-10 (10 ng/mL) alone and in combination for 48 hours. 
The effective apical-to-basolateral permeabilities (Peff) of Gly-Sar 
were measured, and PEPT1 expression was determined using 
reverse transcription-polymerase chain reaction. Results: Gly-Sar 
Peff was similar in burn and sham rats (6.67 ± 2.27 × 10
-5 vs 7.58 
± 2.20 × 10-5 cm/s, respectively, P = .45). In Caco-2 cells, 
cytokine treatment did not alter PEPT1 expression (P = .954) or 
the Peff of Gly-Sar (P = .806). Conclusions: Intestinal absorption of 
the dipeptide Gly-Sar is preserved 24 hours following thermal 
injury in rats. Likewise, PEPT1 expression and peptide absorption 
are preserved following treatment with TNF-α, IL-6, and IL-10 in 
Caco-2 monolayers. These findings imply that intestinal dipeptide 
absorption may be preserved during burn injury. This may lead to 
new strategies to optimize enteral protein delivery in burn patients. 
(JPEN J Parenter Enteral Nutr. 2009;33:520-528) 
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ischemia–reperfusion play an important role in causing 
intestinal dysfunction.12-16 To this end, plasma elevations 
in interleukin (IL)-6 are seen within hours following burn 
injury and exhibit a time course similar to that of 
alterations in intestinal integrity.17,18 Similarly, increases 
in IL-6 production by enterocytes and gut macrophages 
occur within 24 hours of thermal injury.19 Plasma IL-6 
concentrations correlate with burn severity and are 
predictive of outcome, including mortality.18,20-22 Plasma 
tumor necrosis factor (TNF)-α concentrations are 
increased within 2–12 hours following burn injury, and 
TNF-α has also been associated with intestinal permeability 
in burn.23 Clinically, these phenomena may result in 
bacterial translocation from the gut, subsequently leading 
to multiple organ dysfunction.3,6 IL-10 is an anti-
inflammatory cytokine that is also produced following 
burn injury; plasma IL-10 concentrations may also be 
associated with outcome in burn (higher concentrations 
on admission may be associated with increased mortality), 
and IL-10 may attenuate inflammation related changes in 
intestinal cells.24-26
Although many studies have described alterations in 
intestinal barrier function via increased paracellular 
permeability following burn injury, very few have focused 
on potential alterations in nutrient absorption, particularly 
those that are mediated by active processes. The absorption 
of certain amino acids (proline, leucine, glutamic acid, 
and arginine) actively absorbed via a number of transport 
proteins in the small intestine is impaired in experimental 
sepsis models, although it is unknown whether similar 
changes occur in burn.27-31 Of note, others have observed 
a decrease in carrier-mediated glutamine transport in a 
rat burn model.32
The active intestinal absorption of dipeptides and 
tripeptides is mediated by the oligopeptide transporter 
PEPT1 (SLC15A1, h-PEPT1 in humans, r-PEPT1 in 
rats), a proton-coupled transporter present in the brush-
border membrane of the small intestine.33,34 PEPT1 is 
generally considered to be a low-affinity, high-capacity 
transporter that has affinity for a diverse array of substrates, 
although specific structure–activity relationships have 
not been established.34 PEPT1 is also of considerable 
pharmacological importance. In addition to transporting 
oligopeptides, this transporter is also responsible for the 
intestinal absorption of a number of pharmaceuticals, 
including β-lactam antibiotics, renin inhibitors, antivirals, 
antineoplastics, L-valyl ester prodrugs (eg, valacyclovir, 
valgancyclovir), and others.33,34 
The objectives of the current study were twofold. 
First, to evaluate the impact of thermal injury on intestinal 
dipeptide absorption, we studied the absorption of the 
model dipeptide glycylsarcosine (Gly-Sar) in a rat model 
of thermal injury. Second, because of the substantial 
contribution of inflammatory cytokines to burn-induced 
intestinal alterations, we sought to determine the effects 
of the inflammatory cytokines TNF-α and IL-6 and the 
anti-inflammatory cytokine IL-10 on the expression of 
PEPT1 and the permeation of Gly-Sar in cultured human 
intestinal cells (Caco-2 cells). 
Materials and Methods
Materials 
[3H] Gly-Sar was obtained from Moravek Biochemicals 
(Brea, CA), [14C] polyethylene glycol (PEG) 4000 from 
Amersham (Arlington Heights, IL), and [3H] mannitol 
from Sigma Chemical (St. Louis, MO). Dulbecco’s modi-
fied Eagle’s medium, nonessential amino acids, sodium 
pyruvate, Trizol, and 4%–20% tris/borate/EDTA (TBE) 
gels were purchased from Invitrogen Corporation (Carlsbad, 
CA). Heat-inactivated fetal-bovine serum, penicillin-
streptomycin, HEPES buffer (4-[2-hydroxyethyl]-1-piper-
azineethanesulfonic acid), trypsin-versine (EDTA), and 
Scinti-Safe scintillation cocktail were purchased from 
Fisher Scientific (Pittsburgh, PA). Recombinant human 
TNF-α, IL-6, and IL-10 were purchased from Peprotech 
(Rocky Hill, NJ). Cell culture dishes were manufactured 
by Corning Costar (Corning, NY). Enzymes and reagents 
used in reverse transcription-polymerase chain reactions 
(Access RT-PCR kit) were obtained from Promega 
Corporation (Madison, WI). All other chemicals were 
obtained from Sigma Chemical (St. Louis, MO) unless 
otherwise noted.
Dipeptide Permeability Following  
Thermal Injury
Animals. Male Sprague Dawley rats (250–300 g; Charles 
River Laboratories, Wilmington, MA) were housed in 
controlled conditions (12-hour light cycle) and accli-
mated for at least 1 week prior to experiments. All animal 
procedures were approved by the University Committee 
on Use and Care of Animals at the University of Michigan. 
The study conformed to the Guide for the Care and Use 
of Laboratory Animals published by the National Institutes 
of Health (revised in 1996).
Thermal injury model. Animals were assigned to receive 
either burn (n = 7) or sham (n = 8) treatment. Sham rats 
received treatment identical to burn rats with the excep-
tion of the actual burn injury. Rats in the burn group 
received a 30% total body surface area (TBSA) full-thick-
ness scald burn.35 Briefly, following a 12-hour fast (water 
available ad libitum), animals were anesthetized with an 
intraperitoneal injection of sodium pentobarbital (40 mg/
kg). The hair on the dorsal aspect of the rats was shaved, 
and animals were placed in a custom-made insulated 
mold, exposing a portion of their dorsum accounting for 
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30% of their TBSA. Rats assigned to burn treatment were 
immersed in 99°C water for 13 seconds, whereas those 
assigned to sham treatment were immersed in room tem-
perature water for 13 seconds. Following burn injury, rats 
received fluid resuscitation with intraperitoneal lactated 
Ringer’s solution using a modified Parkland formula 
(3 mL/kg per percentage of TBSA burned, two-thirds of 
which was administered immediately following burn 
injury and one-third of which was administered 8 hours 
after injury), and were administered morphine (1.5 mg/kg 
subcutaneously). Following recovery from anesthesia, 
animals were returned to their cages and allowed access 
to food and water ad libitum.
Single pass in situ jejunal perfusion. Twelve hours after burn 
or sham treatment, animals were again fasted, with water 
available ad libitum. Subsequently, 24 hours after burn/
sham treatment, rats were anesthetized with intraperitoneal 
sodium pentobarbital (40 mg/kg) and intramuscular ket-
amine (20 mg/kg). A laparotomy was performed, and a seg-
ment of the proximal jejunum was cannulated at 2 sites with 
plastic tubing, creating a 10-cm closed segment. The seg-
ment was kept moist by placing saline-soaked gauze and 
Parafilm M (Pechiney Plastic Packaging, Chicago, IL) over 
the site. Isotonic buffer solution was perfused through the 
segment at a rate of 0.2 mL/min using a syringe pump (KD 
Scientific, New Hope, PA). The perfusion solution consisted 
of 135 mM NaCl, 5 mM KCl, 5 mM NaOH, 5 mM MES 
(2-[N-morpholino]ethanesulfonic) free acid hydrate, and 
0.5 mM [3H] Gly-Sar. PEG4000 containing a trace amount 
of [14C] PEG4000 was added to the perfusion solution as a 
poorly absorbed marker to account for fluid loss or mem-
brane leakage. The pH of the perfusion solution was 6.5 and 
the osmolarity was adjusted to 290 ± 5 mOsm/L. Outlet 
perfusate was collected at 10-minute intervals. Following 
the 2-hour, closed-loop, in situ perfusion, rats were sacri-
ficed. [3H] Gly-Sar and [14C] PEG4000 concentrations of 
each 10-minute outlet perfusate samples were determined 
using a Beckman LS 6000SC scintillation counter (Beckman 
Instruments, Fullerton, CA).
Data analysis. Absorption was characterized by calculat-
ing the effective permeability of Gly-Sar, as previously 
described.36-39 Briefly, effective permeability was calcu-







where Peff is the effective permeability (cm/s), Q is the 
flow rate of the perfusion solution through the segment 
(0.2 mL/min), Cin and Cout are the inlet and outlet Gly-Sar 
concentrations, R is the intestinal radius (cm; approxi-
mated to be 0.18 cm for all animals), and L is the length 
of the perfused intestinal segment.39 Inlet and outlet con-
centrations were corrected for net absorption or secretion 
of water by multiplying Cout/Cin by [PEG4000]out/
[PEG4000]in. Permeability values reported are mean val-
ues at steady state after excluding outliers. Specifically, if 
the water transport (%/cm) in the segment was > ±1% for 
≥50% of the steady-state time points, mucosal integrity 
was considered compromised and permeability data from 
the animal were excluded from analysis.
Dipeptide Absorption Following  
Cytokine Treatment
Cell culture. Caco-2 cells (passage 40–50) were grown at 
37°C in 5% CO2 in 100-mm culture dishes, in Dulbecco’s 
modified Eagle’s medium, supplemented with 10% fetal 
bovine serum, 1% nonessential amino acids, 1% sodium 
pyruvate, 10 mM HEPES, 100 units/mL penicillin, and 
0.1 mg/L streptomycin. Growth medium was replaced 
thrice weekly. After achieving confluence in 100-mm cul-
ture dishes (5–7 days), cell monolayers were disrupted 
using trypsin-versine and seeded onto permeable colla-
gen-coated polyester supports (3 µm pore diameter) 
(Transwell, Corning Costar) at a density of 100,000 
cells/mL. For permeability experiments, 6.5-mm diameter 
supports were used, whereas 24-mm supports were used 
to obtain RNA for reverse transcription-polymerase chain 
reaction (RT-PCR). Cells were grown on these supports 
in the above conditions for a total of 21 days prior to 
cytokine treatment (see below).
Cytokine treatment. All experiments were conducted in 
triplicate. Prior to cytokine treatment, transepithelial 
electrical resistance (TEER) was measured using an epi-
thelial ohmmeter (EVOM, World Precision Instruments, 
Sarasota, FL); only confluent monolayers (defined as cell 
inserts with TEER ≥200 Ω⋅cm2, corrected for membrane 
resistance) were used in experiments. The following 5 
experimental groups of monolayers were treated with 
cytokines (10 ng/mL, in media as described above, added 
to the basolateral compartments of the cell chambers) for 
48 hours: TNF-α, IL-6, IL-10, TNF-α plus IL-6, and 
TNF-α plus IL-6 plus IL-10. Control cultures were 
treated with normal media.
Absorption. Following cytokine or control treatment, TEER 
was again measured and the effective permeabilities of the 
cell monolayers to Gly-Sar and mannitol were determined. 
Permeability experiments were carried out using an apical 
transport buffer (NaCl 150 mM, KCl 3 mM, NaH2PO4 1 
mM, CaCl2 1 mM, MgCl26H2O 1 mM, MES [2-(N-mor-
pholino)ethanesulfonic acid] 5 mM, D-glucose 5 mM, pH 
6.0) and a basolateral transport buffer (NaCl 150 mM, 
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KCl 3 mM, NaH2PO4 1 mM, CaCl2 1 mM, MgCl26H2O 1 
mM, HEPES 5 mM, D-glucose 5 mM, pH 7.4). [3H] Gly-
Sar (10 mM) or [3H] mannitol (0.22 mM) was added to 
the apical chambers, and basolateral concentrations of 
markers were measured at 0, 15, 30, 45, 60, and 120 
minutes, under sink conditions. [3H] Gly-Sar and [3H] 
mannitol concentrations were measured using a Beckman 
LS 6000SC scintillation counter (Beckman Instruments, 
Fullerton, CA). 
Data analysis. Permeation of Gly-Sar and mannitol was 
characterized using their effective permeability coeffi-
cients (Peff). Permeability coefficients were calculated 





where dQ/dt is the rate of accumulation of substrate in 
the basolateral chamber, A is the surface area of the mem-
brane, and Ca is the initial concentration of substrate in 
the apical chamber, as described previously.40 
PEPT1 expression. The effects of cytokine treatment on 
PEPT1 messenger RNA (mRNA) expression were deter-
mined using semiquantitative RT-PCR as described previ-
ously.41 Caco-2 cells were removed from 24-mm permeable 
supports, and total RNA was isolated using a commer-
cially available RNA isolation kit (TRIzol, Invitrogen 
Corporation, Carlsbad, CA) per the manufacturer’s 
instructions. RNA was converted to complementary DNA 
(cDNA) using a reverse-transcription system (Access 
RT-PCR, Promega, Madison, WI). Briefly, 50-µL reac-
tion mixtures, consisting of 5 units avian myeloblastosis 
virus (AMV) reverse transcriptase, 5 units Tfl DNA poly-
merase, 10 µL 5× AMV/Tfl reaction buffer, 1 mM MgSO4, 
0.2 mM dNTPs (deoxynucleosides), 1 µM each upstream 
and downstream primer (see below), 1 µg total RNA, and 
33 µL nuclease-free water, were prepared. The composi-
tion of the primer pair was as follows: sense 5′-GCAGTC- 
ACCTCAGTAAGCT-3′ and antisense 5′-GCTGCTG- 
ATGTTTGCATA-3′. The PCR reaction was carried out 
using a GeneAmp 2400 thermalcycler (Applied Biosystems, 
Foster City, CA). Following a single cycle of reverse tran-
scription and reverse transcriptase deactivation/RNA-
cDNA primer denaturation (48°C for 45 minutes, then 
94°C for 2 minutes), samples underwent 25 cycles of 
denaturation, annealing, and extension (94°C for 30 sec-
onds, 54°C for 1 minute, and 68°C for 2 minutes) and a 
single final extension (68°C for 1 minute). cDNA samples 
were held at 4°C until gel electrophoresis. The PCR prod-
ucts were separated on 4%–20% TBE gels. Gels were 
stained using SYBR-Green, and densitometric analyses 
were performed using a Kodak photo documentation sys-
tem (Kodak, New Haven, CT).
Statistical analyses. All data are presented as mean ± stan-
dard deviation unless otherwise stated. A 2-tailed Student’s 
t test was used to compare Peff between the burn and 
sham groups. Analysis of variance (ANOVA) models with 
post hoc analyses using Tukey’s test were used in the 
analyses of Gly-Sar Peff and PEPT1 expression in Caco-2 
experiments. All tests were conducted using SPSS 11.0 
(SPSS Inc, Chicago, IL), and for all tests, P ≤ .05 was 
considered to be significant.
Results
Dipeptide Absorption Following Thermal Injury
Data from 2 rats in the burn group were excluded from 
analysis for not meeting the a priori defined criteria for 
water transport as described in the methods section. 
Thus, data from 7 rats in the burn group and 8 rats in the 
sham group were included in the final analysis. Gly-Sar 
permeability was well preserved following thermal injury. 
Specifically, Gly-Sar Peff was 6.67 ± 2.27 × 10
-5 vs 7.58 ± 
2.20 × 10-5 cm/s, in burn and sham rats, respectively (P = .45, 
Figure 1). Fraction of Gly-Sar dose absorbed approached 
100% in both groups (95.0% vs 96.8% in burn and sham 
animals, respectively, P = .38). 
Figure 1. Effective permeability (Peff) of glycylsarcosine (Gly-
Sar) in burn (n = 7) and sham (n = 8) rats following 30% total 
body surface area full-thickness scald injury. P = .45 (Student’s 
t test).
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Dipeptide Absorption Following  
Cytokine Treatment
Gly-Sar and mannitol permeability. The permeability of 
Caco-2 monolayers to Gly-Sar was unaffected by treat-
ment with IL-6, TNF-α, IL-10, or the combinations of 
TNF-α plus IL-6 and TNF-α plus IL-6 plus IL-10; mean 
effective permeabilities ranged from 4.65 × 10-6 cm/s 
(with the combination of TNF-α, IL-6, and IL-10) to 6.09 × 
10-6 cm/s (with IL-6 treatment) (P = .806, Figure 2). 
Similarly, the permeation of mannitol, a passively absorbed 
marker, was also unaltered by cytokine treatment (P = 
.985, Figure 3). Mean mannitol effective permeabilities 
ranged from 0.917 × 10-5 cm/s in IL-10-treated groups to 
1.06 × 10-5 cm/s in control groups (Figure 3).
TEER. TEER was measured in this study prior to and fol-
lowing incubation with cytokines or control media. 
Cytokine treatment resulted in marked changes in the 
overall barrier integrity (P < .001, Figure 4). Post hoc 
analyses confirmed that, compared with controls, treat-
ment with IL-6 alone, and in combination with both 
TNF-α and TNF-α plus IL-10, significantly reduced 
TEER (P < .05 for each comparison). In contrast, treat-
ment with the anti-inflammatory cytokine IL-10 resulted 
in improved monolayer integrity (P < .01, compared with 
all other groups). IL-10 (when combined with IL-6 and 
TNF-α) partially attenuated the effects of IL-6, as the 
reduction in TEER was significantly less than that caused 
by IL-6 alone (P = .004). Complete results of the post hoc 
analysis are shown in Table 1.
PEPT1 expression. Semiquantitative RT-PCR was used to 
determine the effects TNF-α, IL-6, and IL-10 on PEPT1 
mRNA expression. PEPT1 expression was preserved fol-
lowing treatment with each of the cytokines and cytokine 
combinations tested (P = .943, Figure 5).
Discussion
Intestinal barrier function is impaired in burn injury and 
a number of inflammatory conditions.3,13,42-44 Several 
studies offer compelling evidence for the role of inflam-
matory cytokines in the pathogenesis of intestinal hyper-
permeability related to burn injury and other critical 
illness.17,19,23,45-47 The primary focus of the majority of 
these studies has been the paracellular permeation of 
microorganisms and inflammatory stimuli. In contrast, 
few studies have evaluated potential changes in the intes-
tinal absorption of nutrients, specifically those dependent 
on facilitated transport mechanisms. The purpose of this 
study was to evaluate the effects of the profound inflam-
matory response induced by burn injury on peptide 
absorption via the oligopeptide transporter PEPT1. Our 
results indicate that PEPT1 is, in fact, a robust transport 
Figure 2. Effective permeability (Peff) of glycylsarcosine (Gly-
Sar) in Caco-2 monolayers treated with control media, tumor 
necrosis factor (TNF)-α, interleukin (IL)-6, IL-10, TNF-α plus 
IL-6, and TNF-α plus IL-6 plus IL-10 (concentration of all 
cytokines is 10 ng/mL). Bars represent means, lines represent 
standard deviations. P = .806 (ANOVA). 
Figure 3. Effective permeability (Peff) of mannitol in Caco-2 
monolayers treated with control media, tumor necrosis factor 
(TNF)-α, interleukin (IL)-6, IL-10, TNF-α plus IL-6, and 
TNF-α plus IL-6 plus IL-10 (concentration of all cytokines is 10 
ng/mL). Bars represent means, lines represent standard devia-
tions. P = .985 (ANOVA). 
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system. Specifically, the jejunal absorption of Gly-Sar, the 
marker dipeptide used in the study, is unaltered following 
a 30% TBSA full-thickness burn injury in rats. Because 
many of the intestinal changes during burn injury are 
mediated by inflammatory cytokines, we also studied the 
effects of inflammatory cytokines on PEPT1 function and 
expression in cultured intestinal cells (Caco-2 cells). 
Consistent with the results of our animal experiments, 
Gly-Sar permeability and PEPT1 mRNA expression were 
preserved in Caco-2 monolayers treated with IL-6 and 
TNF-α separately, in addition to the combinations of IL-6 
and TNF-α and that of IL-6, TNF-α, and IL-10. Although 
we did not confirm our mRNA results by quantifying 
PEPT1 protein expression, our mRNA expression results 
are supported by our functional studies (ie, Gly-Sar per-
meability) in both animal and in vitro experiments.
In conjunction with the assessment of Gly-Sar 
permeability, we also determined the influence of IL-6, 
TNF-α, and IL-10 on the effective permeability of mannitol 
and the overall integrity of the Caco-2 monolayers (as 
indicated by the electrical resistance posed by the 
membrane [TEER]). The former allowed us to assess 
changes in the absorption of a passively absorbed marker. 
Mannitol permeability in the Caco-2 monolayers was 
Table 1. Results of the Post Hoc Analysis (Tukey’s Test) of Changes in Transepithelial Resistance From Baseline
Treatment Control TNF-α IL-6 IL-10 TNF-α + IL-6 TNF-α + IL-6 + IL-10
Control – NS S S S S
TNF-α NS – S S S S
IL-6 S S – S NS S
IL-10 S S S – S S
TNF-α + IL-6 S S NS S – NS
TNF-α + IL-6 + IL-10 S S S S NS –
TNF, tumor necrosis factor; IL, interleukin; S, significant difference (P ≤ .05); NS, nonsignificant difference (P > .05). Caco-2 
monolayers were treated with treated with control media, TNF-α, IL-6, IL-10, TNF-α plus IL-6, and TNF-α plus IL-6 plus IL-10 
(concentration of all cytokines is 10 ng/mL). Results are pooled results from multiple permeability experiments. 
Figure 4. Change in transepithelial electrical resistance 
(TEER) from baseline of Caco-2 monolayers treated with treated 
with control media, tumor necrosis factor (TNF)-α, interleukin 
(IL)-6, IL-10, TNF-α plus IL-6, and TNF-α plus IL-6 plus IL-10 
(concentration of all cytokines is 10 ng/mL). Results are pooled 
results from multiple permeability experiments. Bars represent 
means; lines represent standard deviations. P < .001 (ANOVA); 
results of post hoc analysis are shown in Table 1.
Figure 5. PEPT1 RNA expression following cytokine treat-
ment. RNA samples were analyzed in triplicate using RT-PCR. 
Results of densitometric analyses are shown: bars represent 
means; lines represent standard deviations. P = .943 (ANOVA). 
TNF, tumor necrosis factor; IL, interleukin.
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unchanged following cytokine treatment. Of note, this 
appears to be in conflict with some of the existing literature 
evaluating the effects of inflammatory cytokines on the 
permeation of passively absorbed macromolecules.12,14,46 
This apparent discordance can be explained by 2 important 
considerations. First, in our study, experiments were 2 
hours in duration, which is much shorter than the duration 
of many of the other studies in which permeability was 
assessed over a period of up to 72 hours. Second, in some 
of the existing studies, model epithelia were incubated 
with cytokines for a longer duration than the 48-hour 
incubation time used in the current study. Cytokine 
treatment resulted in marked changes in the electrical 
resistance posed by the Caco-2 monolayers. In general, 
IL-6 resulted in a generalized reduction in monolayer 
integrity (whether alone or in combination). Although a 
mechanistic explanation for this would be speculative, this 
is not unexpected, because Caco-2 cells express IL-6 
receptors, and IL-6 induces a broad array of effects in 
Caco-2 cells, including nuclear factor-κB activation and 
alterations in monolayer integrity.48-50 In contrast, the anti-
inflammatory cytokine IL-10 appeared to have a protective 
or trophic effect on the Caco-2 monolayers. Over the 
incubation period, TEER increased from baseline in IL-10-
treated monolayers, whereas TEER decreased in all other 
groups (including marginal decreases in control and TNF-
α-treated groups). Moreover, the combination of IL-10 
with TNF-α and IL-6 resulted in significant attenuation of 
the effects of IL-6 compared with treatment with IL-6 
alone, although the attenuation of barrier dysfunction was 
not significant when the combination of all cytokines was 
compared with the combination of TNF-α and IL-6. IL-10 
was assessed because of its clinical importance in burn 
and to determine whether IL-10 attenuates the effect of 
the inflammatory cytokines; similar phenomena have been 
demonstrated in model epithelia by other investigators.26 
Our results may be subject to several criticisms. The 
rat thermal injury model used may not be perfectly 
representative of burn injury in humans. For example, to 
minimize animal distress, rats were anesthetized prior to 
burn injury; this may result in a diminished acute phase 
response compared with that observed clinically. However, 
in previous studies with this model, we have demonstrated 
dramatic changes in jejunal histology and alterations in 
intestinal p-glycoprotein expression, so we are relatively 
confident that the mechanism of injury is sufficient to 
affect absorptive processes influenced by inflammation 
and appropriate to study alterations in active transport 
processes.51 Controversy exists regarding the ideal choice 
of probe to study peptide absorption. Gly-Sar was chosen 
as the model substrate for dipeptide transporters in the 
current study for several reasons: it is hydrolysis resistant, 
numerous mammalian cell culture experiments indicate 
that it is transported by PEPT1, and it has been widely 
used as a prototypical PEPT1 substrate.1 It is possible, 
however, that Gly-Sar is a substrate for other peptide 
transporters in addition to PEPT1. Additionally, computer-
generated conformational analyses of Gly-Sar structure 
and bacterial peptide transporter assays suggest that Gly-
Sar may not be an ideal substrate for some types of 
bacterial peptide transporters (although Gly-Sar is 
transported by the bacterial transporter thought to most 
closely resemble PEPT1).52 Despite these theoretical 
limitations, Gly-Sar is a well-established PEPT1 substrate 
and remains the most widely used probe substrate. In our 
rat burn model, we used PEG4000 to account for fluid 
loss or membrane leakage. Although it is possible that 
some passive absorp tion of PEG4000 occurred, this is 
likely to be insignificant compared with Gly-Sar absorption. 
The concentrations of cytokines used in the in vitro 
portions of the study (10 ng/mL for all cytokines) were 
derived from previously published investigations that have 
used model epithelia to investigate intestinal permeability 
and transporter protein expression.46,53-56 It is possible that 
these concentrations do not reflect physiologic cytokine 
concentrations at the enterocyte level. Unfortunately, the 
concentrations of these cytokines present in and around 
enterocytes in vivo are unknown. Moreover, these 
concentrations are inheren tly difficult to estimate, because 
they may be influenced by cytokine concentrations 
circulating systemi cally as well as cytokines produced 
locally by enterocytes and intraepithelial lymphocytes.56-58 
Use of a physiologically relevant model of disease, in 
conjunction with evaluation using key mediators of 
inflammation in vitro, gives credence to our results. 
Our results suggest that PEPT1 is a robust transport 
protein in burn injury and potentially in other states of 
acute inflammation that are characterized by high levels 
of inflammatory cytokines. Similarly, other investigations 
have described preservation of PEPT1 expression and/or 
function in a variety of conditions. For example, the 
cytokine interferon-γ increases the expression of PEPT1 
and the permeability of Gly-Sar in Caco-2 cells.59 Tanaka 
and colleagues demonstrated that during 5-fluorouracil-
induced intestinal injury in rats, the amount of PEPT1 is 
unaltered and Gly-Sar uptake is unchanged.60 Others 
have demonstrated an increase in PEPT1expression in 
response to starvation.61,62 These studies, taken in the 
context of our current results, suggest that PEPT1-
mediated oligopeptide transport is well preserved in 
conditions of stress. 
Our results have several implications in the context 
of burn injury. Early enteral nutrition is a hallmark of 
burn care, so preservation of oligopeptide absorption 
during burn injury and critical illness may have 
implications with regard to enteral protein delivery, 
especially given the apparent decrease in amino acid 
absorption that occurs and the high protein requirements 
of this patient population.27-32,63,64 PEPT1 is also 
responsible for the absorption of a number of drugs, 
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including β-lactam antibiotics, renin inhibitors, antivirals, 
antineoplastics, and others.40,65-66 Preservation of this 
transport system following burn injury and during 
cytokine-induced challenge suggests that the oral 
absorption of these agents may also be preserved in burn 
injury and other states of inflammation. Moreover, the 
resistance of PEPT1 to a variety of insults supports the 
use of this transport system in the design of future 
nutrition strategies. Finally, PEPT1 may actually play a 
role in perpetuating some inflammatory conditions via 
facilitating the intestinal absorption of bacterial-derived 
peptides, an effect that may be attenuated in vitro with 
PEPT1 substrates.67
Conclusions
Intestinal peptide absorption is preserved following burn 
injury in rats, an effect that was confirmed in Caco-2 
monolayers treated with TNF-α, IL-6, and IL-10. These 
findings imply that intestinal absorption of peptides/pep-
tidomimetic drugs is preserved in burn injury. Future 
efforts should be targeted at exploring the in vivo signifi-
cance of these findings, with the goal of optimizing 
enteral nutrition in burn patients.
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